These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32142251)

  • 1. Identification of Phosphate-Containing Compounds as New Inhibitors of 14-3-3/c-Abl Protein-Protein Interaction.
    Iralde-Lorente L; Tassone G; Clementi L; Franci L; Munier CC; Cau Y; Mori M; Chiariello M; Angelucci A; Perry MWD; Pozzi C; Mangani S; Botta M
    ACS Chem Biol; 2020 Apr; 15(4):1026-1035. PubMed ID: 32142251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3σ case.
    Corradi V; Mancini M; Santucci MA; Carlomagno T; Sanfelice D; Mori M; Vignaroli G; Falchi F; Manetti F; Radi M; Botta M
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6867-71. PubMed ID: 21962576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis.
    Corradi V; Mancini M; Manetti F; Petta S; Santucci MA; Botta M
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6133-7. PubMed ID: 20832303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1.
    Ting PY; Damoiseaux R; Titz B; Bradley KA; Graeber TG; Fernández-Vega V; Bannister TD; Chase P; Nair R; Scampavia L; Hodder P; Spicer TP; Colicelli J
    PLoS One; 2015; 10(3):e0121833. PubMed ID: 25811598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemically stable inhibitors of 14-3-3 protein-protein interactions derived from BV02.
    Iralde-Lorente L; Cau Y; Clementi L; Franci L; Tassone G; Valensin D; Mori M; Angelucci A; Chiariello M; Botta M
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):657-664. PubMed ID: 30727786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
    Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
    J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function.
    Grover P; Shi H; Baumgartner M; Camacho CJ; Smithgall TE
    PLoS One; 2015; 10(7):e0133590. PubMed ID: 26222440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
    Jin F; Gao D; Wu Q; Liu F; Chen Y; Tan C; Jiang Y
    Bioorg Med Chem; 2013 Sep; 21(18):5694-706. PubMed ID: 23932071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.
    Radi M; Crespan E; Botta G; Falchi F; Maga G; Manetti F; Corradi V; Mancini M; Santucci MA; Schenone S; Botta M
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1207-11. PubMed ID: 18078752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
    Zhang C; Tan C; Zu X; Zhai X; Liu F; Chu B; Ma X; Chen Y; Gong P; Jiang Y
    Eur J Med Chem; 2011 Apr; 46(4):1404-14. PubMed ID: 21295380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
    Kumar H; Raj U; Gupta S; Varadwaj PK
    J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
    Huron DR; Gorre ME; Kraker AJ; Sawyers CL; Rosen N; Moasser MM
    Clin Cancer Res; 2003 Apr; 9(4):1267-73. PubMed ID: 12684394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia.
    Sharda S; Sarmandal P; Cherukommu S; Dindhoria K; Yadav M; Bandaru S; Sharma A; Sakhi A; Vyas T; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2017; 17(26):2989-2996. PubMed ID: 28828991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revealing the binding modes and the unbinding of 14-3-3σ proteins and inhibitors by computational methods.
    Hu G; Cao Z; Xu S; Wang W; Wang J
    Sci Rep; 2015 Nov; 5():16481. PubMed ID: 26568041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
    Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
    Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage.
    Raina D; Ahmad R; Kumar S; Ren J; Yoshida K; Kharbanda S; Kufe D
    EMBO J; 2006 Aug; 25(16):3774-83. PubMed ID: 16888623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.